MEG3 and cancer: The expression of MEG3 is downregulated in numerous human primary cancers or cancer cell lines where it functions as an antitumor component or a tumor suppressor, such as glioma, liver, breast, cervical, lung, ovarian, osteosarcoma, colorectal, bladder, prostate, and gastric cancer cells [223].